Screening for prostate cancer in U.S. men ACPM position statement on preventive practice

Area of Science:

• Oncology
• Preventive Medicine
• Urology

Background:

• Prostate cancer is a leading cancer in U.S. men.
• Digital rectal examination (DRE) and prostate-specific antigen (PSA) are principal screening tests.
• Limited randomized controlled trials exist, with more ongoing.

Purpose of the Study:

• To review the efficacy of DRE and PSA for prostate cancer screening.
• To summarize current evidence on prostate cancer screening benefits and limitations.

Main Methods:

• Literature review of studies published before July 2007.
• Analysis of applications of PSA screening tests in clinical practice.

Main Results:

• PSA screening applications include various cutoffs and measures (e.g., PSA velocity, free PSA).
• Screening may detect early disease but benefits remain unproven.
• No convincing evidence shows early screening improves mortality; risks include false results and treatment side effects.

Conclusions:

• Insufficient evidence to recommend routine population screening with DRE or PSA.
• Clinicians should discuss benefits, risks, and evidence limitations with patients, especially high-risk individuals.
• Informed decision-making is crucial for prostate cancer screening.